Walter Reinisch focuses on Internal medicine, Gastroenterology, Surgery, Ulcerative colitis and Inflammatory bowel disease. His research in Internal medicine tackles topics such as Placebo which are related to areas like Clinical endpoint. His Gastroenterology study integrates concerns from other disciplines, such as Area under the curve, Azathioprine, Fecal bacteriotherapy and Mesalazine.
His work deals with themes such as Crohn's Disease Activity Index, Adalimumab, Clinical trial and C-reactive protein, which intersect with Surgery. The Ulcerative colitis study combines topics in areas such as Maintenance therapy, Colitis and Diarrhea. His Inflammatory bowel disease research incorporates elements of Physical therapy, Immunology, Prospective cohort study and Intensive care medicine.
Walter Reinisch mainly focuses on Internal medicine, Gastroenterology, Crohn's disease, Ulcerative colitis and Inflammatory bowel disease. His research combines Surgery and Internal medicine. His research in Gastroenterology focuses on subjects like Placebo, which are connected to Clinical endpoint.
His studies in Crohn's disease integrate themes in fields like Post-hoc analysis, Randomized controlled trial and Immunology. He has researched Ulcerative colitis in several fields, including Tofacitinib, Colitis, Clinical trial, Adverse effect and Golimumab. His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Prospective cohort study and Intensive care medicine.
The scientist’s investigation covers issues in Internal medicine, Ulcerative colitis, Crohn's disease, Gastroenterology and Inflammatory bowel disease. Internal medicine and Placebo are frequently intertwined in his study. The study incorporates disciplines such as Tofacitinib, Open label, Extension study, Addressin and Antibody in addition to Ulcerative colitis.
The various areas that Walter Reinisch examines in his Crohn's disease study include Post-hoc analysis, Adalimumab and Intensive care medicine. In his research on the topic of Gastroenterology, Feces is strongly related with Calprotectin. His Inflammatory bowel disease research is multidisciplinary, incorporating elements of Logistic regression, Clinical trial, Arthritis, Golimumab and Quality of life.
Internal medicine, Crohn's disease, Ulcerative colitis, Gastroenterology and Inflammatory bowel disease are his primary areas of study. In his research, Clinical endpoint is intimately related to Placebo, which falls under the overarching field of Internal medicine. The concepts of his Crohn's disease study are interwoven with issues in Adalimumab, Immunology and C-reactive protein.
His Ulcerative colitis study incorporates themes from Patient-reported outcome, Tofacitinib, Colitis, Incidence and Cancer research. His Stool frequency study in the realm of Gastroenterology connects with subjects such as Neoadjuvant therapy. His Inflammatory bowel disease research integrates issues from Multiple sclerosis, Golimumab, Clinical trial and Arthritis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Paul Rutgeerts;William J Sandborn;Brian G Feagan;Walter Reinisch.
The New England Journal of Medicine (2005)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Jean Frédéric Colombel;William J. Sandborn;Walter Reinisch;Gerassimos J. Mantzaris.
The New England Journal of Medicine (2010)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass;James O. Lindsay;Andreas Sturm;Alastair Windsor.
Journal of Crohn's and Colitis (2012)
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L. Peyrin-Biroulet;W. Sandborn;B. E. Sands;W. Reinisch;W. Reinisch.
The American Journal of Gastroenterology (2015)
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Wolfgang Hueber;Bruce E Sands;Steve Lewitzky;Marc Vandemeulebroecke.
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn;Gert van Assche;Walter Reinisch;Jean–Frederic Colombel.
Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial
Paul Moayyedi;Michael G. Surette;Peter T. Kim;Peter T. Kim;Josie Libertucci.
Second European Evidence-Based Consensus on the Diagnosis and Management of Ulcerative Colitis Part 1: Definitions and Diagnosis
Axel Dignass;Rami Eliakim;Fernando Magro;Christian Maaser.
Journal of Crohn's and Colitis (2012)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Jean-François Rahier;F Magro;C Abreu;A Armuzzi.
Journal of Crohn's and Colitis (2009)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations
Gert Van Assche;Axel Dignass;Walter Reinisch;C. Janneke van der Woude.
Journal of Crohns & Colitis (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: